Oesophageal varices bleeding is the most severe complication of portal hypertension and is the main cause of death for cirrhosis-related diseases. Endoscopic injection sclerotherapy is widely used procedure for patients with variceal hemorrhage. Endoscopic injection sclerotherapy is the most established method for controlling bleeding of the variceal worlwide.
Endoscopic injection sclerotherapy acts as the main principal for first line intervention in patients with oesophageal varices bleeding in long duration prevention of recurrent bleeding and also during the acute event. Endoscopic injection sclerotherapy is designed to control the initial bleeding and also in preventing bleeding by thickening the mucosa or thrombosing the veins.
In endoscopic injection sclerotherapy, mostly sclerosants are widely used. Some of the common sclerosants that are used in endoscopic injection sclerotherapy are ethanolamine oleate, N-butyl-cyanoacrylate, sodium tetradecyl phosphate, 5% phenol in almond oil and sodium mor-rhuate.
To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/28615
According to World Gastroenterology Organisation guidelines, in 2014, prevalence of gastroesophageal varices is estimated to be 50% in cirrhosis patients and the prevalence of gastric varies are found to be 5 to 33% in patients with portal hypertension. In addition to this, the frequency of esophageal varices vary from 30% to 70% in patients with portal hypertension.
The global endoscopic injection sclerotherapy market is expected to manifest substantial growth in the endoscopic injection sclerotherapy market due to its effectiveness in treatment of variceal hemorrhage.
Moreover, manufacturers are also providing reimbursement guidelines for endoscopic injection sclerotherapy which as a result the endoscopic injection sclerotherapy is shown to have increase in growth in coming years. Since it is safe and easy to administer and can be performed as an outpatient procedure, the endoscopic injection sclerotherapy market is expected to register significant growth in the market.
Endoscopic injection sclerotherapy is the most widely used procedure in emergency treatment of patients with esophageal varices who has active bleeding. All these factors is expected to drive the global endoscopic injection sclerotherapy market.
However, there are certain limitation which is likely to hamper the growth of the endoscopic injection sclerotherapy market. Lack of skilled endoscopist and administration of specific injection technique may affect the growth of the endoscopic injection sclerotherapy market.
In addition to this, the use of ancillary devices which includes balloon tamponade, overtubes and continuous breaching of the mucosa, potential for systemic and pulmonary spread of sclerosant through portal venous collaterals are some of the complications which is likely to hamper the growth of the endoscopic injection sclerotherapy market.
Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/28615
The global endoscopic injection sclerotherapy market is segmented on the basis of route of administration and distributional channel
- Market Segmentation by Route of Administration
- Market Segmentation by Distributional Channel
- Retail Pharmacies
- Mail Order Pharmacies
- Drug Stores
Geographically, endoscopic injection sclerotherapy market is categorized into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the endoscopic injection sclerotherapy market due to advancement in healthcare facilities and adoption of new technologies and therapies which is likely to administer the growth of the endoscopic injection sclerotherapy market.
Europe is also contributing substantial revenue in the endoscopic injection sclerotherapy market owing to increase in cirrhosis and endoscopic injection sclerotherapy procedure which is likely to anticipate growth in endoscopic injection sclerotherapy market.
Asia Pacific has the potential to grow the endoscopic injection sclerotherapy market due to high demand of new technologies and increase in disposable income. Also government and NGO’s initiative in spreading awareness among people about endoscopic sclerotherapy will drive the endoscopic injection sclerotherapy market.
Middle East and Africa is shown to have less contribution in endoscopic injection sclerotherapy market due to lack of proper healthcare infrastructure and poor healthcare facilities which may hamper the growth of the endoscopic injection sclerotherapy market.
Some of the key players leading in endoscopic injection sclerotherapy market are: Mylan, Merz Aesthetics, Questcor Pharmaceuticals, Inc, Biocompatibles UK Ltd, Bioniche Pharma USA, Inc,
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/28615
The report covers exhaustive analysis on:
- Endoscopic Injection Sclerotherapy Market Segments
- Endoscopic Injection Sclerotherapy Market Dynamics
- Historical Actual Market Size, 2014 – 2018
- Endoscopic Injection Sclerotherapy Market Size & Forecast 2019 to 2029
- Endoscopic Injection Sclerotherapy Current Trends/Issues/Challenges
- Competition & Companies involved
- Endoscopic Injection Sclerotherapy Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size Recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance